NASDAQ : ARTL
Artelo Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.22M |
| Enterprise Value | -2.93M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 547,773 |
| Shares Outstanding | 547,773 |
| Shares Change (YoY) | +502.96% |
| Shares Change (QoQ) | +266.98% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 2.38% |
| Float | 547,420 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.21 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.00 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.04 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -705.71% |
| Return on Assets (ROA) | -127.92% |
| Return on Invested Capital (ROIC) | -306.25% |
| Return on Capital Employed (ROCE) | -221.20% |
| Weighted Average Cost of Capital (WACC) | 24.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.81M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -97.67% |
| 50-Day Moving Average | 4.29 |
| 200-Day Moving Average | 21.77 |
| Relative Strength Index (RSI) | 28.91 |
| Average Volume (20 Days) | 40,325 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 34,740 |
| Short Previous Month | 46,160 |
| Short % of Shares Out | 6.34% |
| Short % of Float | 6.35% |
| Short Ratio (days to cover) | 0.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.07M |
| Pretax Income | -12.67M |
| Net Income | -12.67M |
| EBITDA | n/a |
| EBIT | -11.07M |
| Earnings Per Share (EPS) | -$102.42 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.20M |
| Total Debt | 49,000 |
| Net Cash | 4.15M |
| Net Cash Per Share | $7.57 |
| Equity (Book Value) | 5.00M |
| Book Value Per Share | 10.74 |
| Working Capital | 2.92M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -802,000 |
| Free Cash Flow | -12.63M |
| FCF Per Share | -$23.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -502.96% |
| Shareholder Yield | -502.96% |
| Earnings Yield | -4,613.29% |
| FCF Yield | -1,038.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |